[EN] COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE [FR] COMPOSÉS AYANT UN EFFET SUR DE MULTIPLES RÉCEPTEURS DES PROSTAGLANDINES ET PERMETTANT D'OBTENIR UNE RÉPONSE ANTI-INFLAMMATOIRE GÉNÉRALE
[EN] COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE [FR] COMPOSÉS AYANT UN EFFET SUR DE MULTIPLES RÉCEPTEURS DES PROSTAGLANDINES ET PERMETTANT D'OBTENIR UNE RÉPONSE ANTI-INFLAMMATOIRE GÉNÉRALE
[EN] PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS<br/>[FR] DÉRIVÉS DE PIPÉRIDINE POUVANT ÊTRE UTILISÉS EN TANT QU'AGONISTES DE L'OREXINE
申请人:GLAXO GROUP LTD
公开号:WO2010072722A1
公开(公告)日:2010-07-01
This invention relates to imidazopyridylmethylene substituted piperidine derivatives orexin antagonists and their use as pharmaceuticals.
这项发明涉及咪唑吡啶甲基取代哌啶衍生物促睡素拮抗剂及其作为药物的用途。
PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS
申请人:Alvaro Giuseppe
公开号:US20110257198A1
公开(公告)日:2011-10-20
Disclosed are imidazopyridylmethylene substituted piperidine derivatives of Formula (I):
useful as orexin antagonists.
本发明涉及一种公式(I)的咪唑吡啶基亚甲基取代的哌啶衍生物,其作为促进觉醒激素拮抗剂具有实用性。
COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE
申请人:ALLERGAN, INC.
公开号:US20130184463A1
公开(公告)日:2013-07-18
The present invention provides a compound, that is a 1-(halo-2-[(2-hydrocarbyl or substituted hydrocarbyl)oxy]phenyl}methyl)-(fused bicyclic nitrogen heteroaryl) carboxylic acid or an ester or sulfonamide thereof. The compound may be represented by the following formula
Wherein R
1
, R
2
, R
3
, R
4
A, X, W, Z and Y are as defined in the specification. The compounds may be administered to treat DP, FP, EP1, TP and/or EP4 receptor-mediated diseases or conditions.
Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
申请人:ALLERGAN, INC.
公开号:US10392382B2
公开(公告)日:2019-08-27
The present invention provides a compound, that is a 1-(halo-2-[(2-hydrocarbyl or substituted hydrocarbyl)oxy]phenyl}methyl)-(fused bicyclic nitrogen heteroaryl) carboxylic acid or an ester or sulfonamide thereof. The compound may be represented by the following formula
Wherein R1, R2, R3, R4 A, X, W, Z and Y are as defined in the specification. The compounds may be administered to treat DP, FP, EP1, TP and/or EP4 receptor-mediated diseases or conditions.